secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2022-03-08T23:59:59+00:00
Accession:  0001171843-22-001706
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika reports Q4 2021 revenue $35.8M (+10% YoY); full year $147.8M (+13%); guides FY2022 low-to-mid single digit growth
--------------------------------------------------------------------------------

- Q4 2021 revenue $35.8M (+10% YoY); net loss $5.8M ($0.40 diluted) vs $15.7M loss prior year.
- Full-year 2021 revenue $147.8M (+13% YoY); net income $4.1M ($0.28 diluted) vs $24.0M loss in 2020.
- Adjusted net loss Q4 $3.2M ($0.23 diluted) vs adjusted net income $1.7M prior year; adjusted EBITDA loss $0.2M vs $4.0M.
- FY2022 guidance: revenue growth low-to-mid single digit; Joint Preservation mid-single to low-double digit, OA Pain low-single digit.
- Cash balance $94.4M; operating cash flow $9.0M for full year; completed enrollment of Cingal pilot trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184322001706/0001171843-22-001706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184322001706/f8k_030822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-001706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer